| Ytd | -0.80% | |
| 1y | 18.10% |
| Open | 1.34 | Prev Close | 1.34 | Low | 1.20 | High | 1.34 | Mkt Cap | 66.13M |
| Vol | 253.82K | Avg Vol | 368.46K | EPS | -1.48 | P/E | N/A | Forward P/E | -0.96 |
| Beta | 1.48 | Short Ratio | 5.17 | Inst. Own | 83.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.26 | 200-d Avg | 1.30 | 1yr Est | 5.80 |
Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse
PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse
PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.40) per share which met the analyst consen
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Mole
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study
PMV Pharma's Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight t
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.41) per share which missed the analyst con
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(1.14) per share which missed the analyst con
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.37) per share which missed the analyst con
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.02) per share which beat the analyst conse
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", )))) t
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst conse
Jefferies analyst Kambiz Yazdi initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating a
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586)
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
Fiscal Year 2023 Financial ResultsAs of December 31, 2023, PMV Pharma had $228.6 million in cash, ca
Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as o
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on PMV Pharma (NASDAQ:PMVP) with a B
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse
HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lo
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the comp
PMV Pharmaceuticals Inc (NASDAQ: PMVP) announced updated Phase 1 results from its ongoing Phase 1/2
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC Intern
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and d
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enh
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in
HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lo
Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesd
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.38) per share which beat the analyst conse